Surgery after Peptide Receptor Radionuclide Therapy (PRRT) in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

被引：0
|
作者：
Bertani, E. [1 ]
Chiappa, A. [1 ]
Fazio, N. [1 ]
Grana, C. [1 ]
Bodei, L. [1 ]
Falconi, M. [2 ]
Ravizza, D. [1 ]
Spada, F. [1 ]
Andreoni, B. [1 ]
机构：
[1] European Inst Oncol, Milan, Italy
[2] Univ Politecn Marche, Pancreas Surg Unit, Ancona, Italy
来源：
NEUROENDOCRINOLOGY | 2014年 / 99卷 / 3-4期
关键词：
neuroendocrine tumors; peptide receptor radionuclide therapy; surgery; survival; progression-free survival;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
O2
引用
收藏
页码：285 / 285
页数：1
相关论文
共 50 条
  • [21] The role of 177LuDotatate peptide receptor radionuclide treatment in patients with metastatic well differentiated gastroenteropancreatic neuroendocrine neoplasms (GEP-NETs)
    Severi, S.
    Sansovini, M.
    Ianniello, A.
    Ambrosetti, A.
    Monti, M.
    Scarpi, E.
    Di Iorio, V.
    D'Errico, V.
    Ibrahim, T.
    Paganelli, G.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S140 - S140
  • [22] Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review
    Camus, Baptiste
    Cottereau, Anne-Segolene
    Palmieri, Lola-Jade
    Dermine, Solene
    Tenenbaum, Florence
    Brezault, Catherine
    Coriat, Romain
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (06) : 1 - 18
  • [23] Toxicity identification and evaluation of peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NETs)
    Duan, Heying
    Girod, Bradley
    Ninatti, Gaia
    Ferri, Valentina
    Kunz, Pamela
    Fisher, George
    Moradi, Farshad
    Davidzon, Guido
    Franc, Benjamin
    Iagaru, Andrei
    Aparici, Carina Mari
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [24] Current role of Nuclear Medicine in the diagnosis and therapy of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
    Georgakopoulos, Alexandros
    HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2023, 26 : 49 - 51
  • [25] Comprehensive genomic profiling of 724 gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Puccini, Alberto
    Poorman, Kelsey
    Salem, Mohamed E.
    Goldberg, Richard M.
    Shields, Anthony Frank
    Xiu, Joanne
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Closer Look at the Characteristics of These Diverse Tumors
    Pape, Ulrich-Frank
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2014, 12 (12) : 8 - 11
  • [27] The Clinical Impact of Serum Chromogranin-A in Patients With Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS)
    Wu, S.
    Reta-Impey, P.
    Manivannan, N.
    Fu, P.
    Cao, S.
    Asa, S.
    Tirumani, S. H.
    Davidson, J.
    Kardan, A.
    Avril, N.
    Wojtylak, P.
    Bajor, D.
    Lee, R.
    Selfridge, E.
    Saltzman, J.
    Ammori, J.
    Hardacre, J.
    Winter, J.
    Mohamed, A.
    PANCREAS, 2021, 50 (03) : 450 - 450
  • [28] Outcome prediction in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) treated with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT): results from a prospective phase II clinical trial
    Mileva, M.
    Marin, G.
    Levillain, H.
    Artigas, C.
    Van Bogaert, C.
    Marin, C.
    Danieli, R.
    Deleporte, A.
    Jungels, C.
    Vanderlinden, B.
    Wimana, Z.
    Hendlisz, A.
    Flamen, P.
    Karfis, I.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S106 - S106
  • [29] Intestinal obstruction (IO) in patients receiving peptide receptor radionuclide therapy (PRRT) for gastro-enteropancreatic neuroendocrine tumors (GEP-NETs): Potential predictors and association with overall survival (OS)
    Badawy, M.
    Hobday, T.
    Johnson, G.
    Halfdanarson, T.
    Young, J.
    Packard, A.
    Thorpe, M.
    Jain, M.
    Eiring, R.
    Patton, C.
    Gansen, D.
    Kendi, A.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 173 - 173
  • [30] Outcomes of peptide receptor radionuclide therapy (PRRT) in metastatic grade 3 neuroendocrine tumors (NETs).
    Lung, Mei Sim
    Hofman, Michael
    Kong, Grace
    Thang, Sue-Ping
    Michael, Michael
    Hicks, Rodney J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345